Market Overview

UPDATE: Goldman Sachs Upgrades Hill-Rom Holdings to Buy Hospita Bed Market Rebound

Related HRC
Walgreens-Greater Than AIDS Unite to Serve Against HIV/AIDS
Hologic Receives Extended FDA Clearance for SculpSure in US

Goldman Sachs raised its rating on Hill-Rom Holdings (NYSE: HRC) from Neutral to Buy and increased its price target from $30 to $39.

Goldman Sachs commented, "Our Buy rating is based on the following: (1) a stabilization and potential improvement in the company's core bed business, notably in the US, which should help drive a positive inflection point on the top line in the near to intermediate term; (2) International expansion helping to support longer term results; and (3) an improved outlook on the company's M&A strategy."

Hill-Rom Holdings closed at $28.07 on Monday.

Latest Ratings for HRC

Jun 2017NeedhamInitiates Coverage OnBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnNeutral
Feb 2017BarclaysInitiates Coverage OnOverweight

View More Analyst Ratings for HRC
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (HRC)

View Comments and Join the Discussion!

Partner Center